Clinical trial
A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer
NCT00596648 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer
- Lead sponsor
- Exelixis
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 12, 2008
- Completion date
- August 2, 2012
- Enrollment
- 92 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.